| No. of Publications | TOTAL IF | AVERAGE IF | |
| Articles | 1,305 | 8,912 | 6.83 |
| Reviews | 233 | 1,831 | 7.86 |
| Editorials | 54 | 328 | 6.08 |
| Scientific Letters | 49 | 303 | 6.19 |
| Total* | 1,641 | 11,375 | 6.93 |
| *Clinical Trials | 112 | 1,513 | 13.51 |
| *Clinical Guidelines | 68 | 538 | 7.92 |
1,641
No. of Publications
11,375
Total IF
6.93
Average IF
59.0%
%Q1
23.0%
%D1
40.5%
%Leadership
2.71
Crown (2017-2021)
25.2%
HCP10% (2017-2021)
51.7%
%Q1 in leadership
54.6%
% Open Access
52.3%
% Int. Collaboration
46.6%
% Female in leadership
Evolution in the last 5 years
Publications by type
Distribution of publications per quartiles and first decile
969 (59.0%)
Q1
409 (24.9%)
Q2
263 (16.0%)
Q3+Q4
378 (23.0%)
D1
39.0%
%D1 in Q1
Publications by areas & Groups
Oncology
185
PUBLICATIONS
64.3%
%Q1
1,287
TOTAL IF
6.95
AVERAGE IF
| Groups | No. of Publications | %Q1 | TOTAL IF | AVERAGE IF |
| Biomedical Research in Gynecology | 25 | 76.0% | 134 | 5.36 |
| Biomedical Research in Urology | 11 | 36.4% | 43 | 3.89 |
| Translational Molecular pathology | 68 | 57.4% | 402 | 5.91 |
| Biomedical Research in Cancer Stem Cells | 13 | 46.2% | 101 | 7.75 |
| Translational Research in Child and Adolescent Cancer | 52 | 71.2% | 482 | 9.27 |
| Biomedical Research in Melanoma | 8 | 50.0% | 33 | 4.16 |
| Biomedical Research in Digestive Tract Tumors | 5 | 80.0% | 29 | 5.74 |
| Drug Delivery and Targeting | 18 | 77.8% | 132 | 7.35 |
| Signalling and New Therapeutic Targets | 6 | 83.3% | 58 | 9.64 |
Vascular Biology and Metabolism (VAM)
340
PUBLICATIONS
63.8%
%Q1
2,180
TOTAL IF
6.41
AVERAGE IF
| Groups | No. of Publications | %Q1 | TOTAL IF | AVERAGE IF |
| Cardiovascular Diseases | 132 | 56.8% | 1,004 | 7.60 |
| Diabetes and Metabolism | 45 | 57.8% | 224 | 4.97 |
| Nephrology and Kidney Transplant | 57 | 84.2% | 310 | 5.44 |
| Neurovascular diseases | 36 | 83.3% | 314 | 8.72 |
| Kidney physiopathology | 33 | 69.7% | 151 | 4.59 |
| Ophthalmology | 14 | 50.0% | 64 | 4.57 |
| Medical Molecular Imaging | 35 | 51.4% | 195 | 5.57 |
| Research on Aging, Frailty and Transitions in Barcelona | 16 | 56.3% | 81 | 5.08 |
Neurosciences
377
PUBLICATIONS
60.2%
%Q1
2,687
TOTAL IF
7.13
AVERAGE IF
| Groups | No. of Publications | %Q1 | TOTAL IF | AVERAGE IF |
| Neuromuscular and mitochondrial pathology | 11 | 54.5% | 50 | 4.53 |
| Psychiatry, mental health and addictions | 63 | 46.0% | 346 | 5.49 |
| Pediatric Neurology | 37 | 43.2% | 185 | 5.00 |
| Clinical neuroimmunology | 68 | 60.3% | 558 | 8.20 |
| Neurotraumatology and Neurosurgery Research Unit (UNINN) | 44 | 65.9% | 323 | 7.34 |
| Neurodegenerative diseases | 23 | 65.2% | 159 | 6.91 |
| Cell signaling and apoptosis | 3 | 66.7% | 17 | 5.61 |
| Headache and Neurological Pain | 33 | 72.7% | 413 | 12.52 |
| Peripheral Nervous System | 3 | 33.3% | 11 | 3.82 |
| Clinical and Translational Bioinformatics | 5 | 80.0% | 31 | 6.20 |
| Gene Therapy at Nervous System | 7 | 85.7% | 45 | 6.45 |
| Stroke Research | 53 | 79.2% | 404 | 7.63 |
| Neuroradiology | 27 | 66.7% | 251 | 9.31 |
| Research group on Status Epilepticus and Acute Seizures | 27 | 22.2% | 106 | 3.94 |
Infectious Diseases
327
PUBLICATIONS
59.3%
%Q1
2,367
TOTAL IF
7.24
AVERAGE IF
| Groups | No. of Publications | %Q1 | TOTAL IF | AVERAGE IF |
| Infectious Diseases | 120 | 57.5% | 780 | 6.50 |
| Microbiology | 86 | 57.0% | 494 | 5.75 |
| Clinical Research/Innovation in Pneumonia & Sepsis (CRIPS) | 30 | 43.3% | 164 | 5.47 |
| Shock, Organ Dysfunction and Resuscitation | 67 | 59.7% | 638 | 9.52 |
| Infection in immunocompromised pediatric patients | 54 | 63.0% | 437 | 8.10 |
| Epidemiology and public health | 26 | 42.3% | 186 | 7.17 |
| Design and pharmacodynamics of nanoparticles | 16 | 100.0% | 132 | 8.23 |
| Diagnostic Nanotools (DINA) | 5 | 80.0% | 33 | 6.53 |
Digestive and Liver Diseases
144
PUBLICATIONS
57.6%
%Q1
1,148
TOTAL IF
7.97
AVERAGE IF
| Groups | No. of Publications | %Q1 | TOTAL IF | AVERAGE IF |
| Liver diseases | 89 | 59.6% | 825 | 9.27 |
| Physiology and Pathophysiology of the Digestive Tract | 44 | 56.8% | 278 | 6.31 |
| Multidisciplinary Nursing Research Group | 14 | 35.7% | 53 | 3.75 |
Immunomediated Diseases and Innovative Therapies
315
PUBLICATIONS
54.9%
%Q1
2,256
TOTAL IF
7.16
AVERAGE IF
| Groups | No. of Publications | %Q1 | TOTAL IF | AVERAGE IF |
| Pneumology | 99 | 45.5% | 766 | 7.74 |
| Systemic diseases | 81 | 59.3% | 532 | 6.57 |
| Translational Immunology | 27 | 88.9% | 240 | 8.90 |
| Clinical Pharmacology | 28 | 50.0% | 195 | 6.96 |
| Gene and Cell Therapy | 1 | 100.0% | 6 | 5.70 |
| Transfusional Medicine | 19 | 47.4% | 84 | 4.41 |
| Rheumatology | 31 | 71.0% | 278 | 8.96 |
| Clinical Biochemistry | 37 | 54.1% | 254 | 6.87 |
| Donation and transplantation of organs, tissues and cells | 10 | 70.0% | 46 | 4.65 |
Research in Surgery
137
PUBLICATIONS
52.6%
%Q1
692
TOTAL IF
5.05
AVERAGE IF
| Groups | No. of Publications | %Q1 | TOTAL IF | AVERAGE IF |
| New Technologies and Craniofacial Microsurgery | 6 | 83.3% | 151 | 25.22 |
| Spine Research Unit | 13 | 46.2% | 46 | 3.51 |
| General Surgery | 90 | 57.8% | 473 | 5.26 |
| Reconstructive surgery of the locomotor system | 13 | 23.1% | 45 | 3.45 |
| Musculoskeletal Tissue Engineering | 10 | 40.0% | 39 | 3.94 |
| Research Group of Physical Medicine and Rehabilitation | 9 | 55.6% | 33 | 3.63 |
Obstetrics, Pediatrics and Genetics
82
PUBLICATIONS
43.9%
%Q1
460
TOTAL IF
5.61
AVERAGE IF
| Groups | No. of Publications | %Q1 | TOTAL IF | AVERAGE IF |
| Maternal Fetal Medicine | 27 | 51.9% | 135 | 4.99 |
| Genetics Medicine | 19 | 47.4% | 102 | 5.39 |
| Growth and Development | 30 | 43.3% | 217 | 7.25 |
| Bioengineering, Cell Therapy and Surgery in Congenital Malformations | 13 | 15.4% | 31 | 2.37 |
Normalized Impact & Excellence by areas (*)
Crown Index 2017-2021
Highly Cited Papers 10% (HCP10%) 2017-2021
(*)CROWN and HCP10% indicators take into account articles and reviews from 2017 to 2021, and are calculated using Clarivate’s ESI (Essential Science indicators) baseline citation rates and baseline percentiles from its 10/03/2022 update.
CROWN indicator shows the relative number of citations to publications, compared to the global average of citations to publications of the same type, year of publication and thematic area, being 1 the baseline or world average.
HCP10% (Highly Cited Papers 10%) shows the publications included in 10% of the world’s most cited publications of the same type, year of publication and subject area, being 10% the expected value (higher is better).
Citations to calculate the CROWN and HCP10% indicators were downloaded from Clarivate WoS (Web of Science) Core Collection on 15/03/2022. Citation count is not fractional.
Leadership by areas (**)
| %Leadership | %Q1 in leadership | %Female in leadership | |
| VHIR | 40.5% | 51.7% | 46.6% |
| Areas | |||
| Oncology | 35.7% | 66.7% | 58.8% |
| Vascular Biology and Metabolism (VAM) | 40.9% | 61.9% | 49.1% |
| Neurosciences | 32.4% | 52.5% | 48.3% |
| Infectious Diseases | 28.4% | 46.2% | 38.6% |
| Digestive and Liver Diseases | 36.8% | 50.9% | 52.4% |
| Immunomediated Diseases and Innovative Therapies | 37.8% | 42.9% | 51.1% |
| Research in Surgery | 35.8% | 49.0% | 11.9% |
| Obstetrics, Pediatrics and Genetics | 35.4% | 41.4% | 60.7% |
(**) Leadership indicators take into account first, last and/or corresponding author
Open Access (***)
54.6%
OPEN ACCESS
45.4%
CLOSED & BRONZE ACCESS
(***) Open Access takes into account green, gold and hybrid route publications, according to the Unpaywall database.
Open Access by areas
| Areas | % Open Access |
| Oncology | 56.20% |
| Vascular Biology and Metabolism (VAM) | 50.90% |
| Neurosciences | 59.90% |
| Infectious Diseases | 54.40% |
| Digestive and Liver Diseases | 61.80% |
| Immunomediated Diseases and Innovative Therapies | 53.70% |
| Research in Surgery | 39.40% |
| Obstetrics, Pediatrics and Genetics | 51.20% |
Publications in high influence journals (****)
| Journal | No. of Publications | Journal’s Impact Factor (JCR 2020) |
| NEW ENGLAND JOURNAL OF MEDICINE | 5 | 91.253 |
| LANCET | 3 | 79.323 |
| JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1 | 56.274 |
| Nature Reviews Disease Primers | 2 | 52.329 |
| NATURE | 3 | 49.962 |
| JOURNAL OF CLINICAL ONCOLOGY | 3 | 44.544 |
| LANCET NEUROLOGY | 4 | 44.182 |
| Nature Reviews Neurology | 2 | 42.937 |
| LANCET ONCOLOGY | 4 | 41.316 |
| Cancer Discovery | 1 | 39.397 |
| NATURE GENETICS | 1 | 38.330 |
| ANNALS OF ONCOLOGY | 1 | 32.976 |
| Lancet Respiratory Medicine | 5 | 30.700 |
| EUROPEAN HEART JOURNAL | 3 | 29.983 |
| Journal of Extracellular Vesicles | 1 | 25.841 |
| JOURNAL OF HEPATOLOGY | 11 | 25.083 |
| LANCET INFECTIOUS DISEASES | 2 | 25.071 |
| JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 7 | 24.093 |
| BLOOD | 1 | 23.629 |
| GUT | 2 | 23.059 |
| GASTROENTEROLOGY | 5 | 22.682 |
| AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 1 | 21.405 |
| AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE | 1 | 21.405 |
| Nano Today | 1 | 20.722 |
| DIABETES CARE | 1 | 19.112 |
| ANNALS OF THE RHEUMATIC DISEASES | 2 | 19.103 |
| JAMA Neurology | 7 | 18.302 |
| Nature Microbiology | 1 | 17.745 |
| Science Immunology | 3 | 17.727 |
| INTENSIVE CARE MEDICINE | 7 | 17.440 |
| HEPATOLOGY | 2 | 17.425 |
| BASIC RESEARCH IN CARDIOLOGY | 2 | 17.165 |
| NUCLEIC ACIDS RESEARCH | 1 | 16.971 |
| EUROPEAN RESPIRATORY JOURNAL | 2 | 16.671 |
| FEMS MICROBIOLOGY REVIEWS | 1 | 16.408 |
| JAMA Pediatrics | 1 | 16.193 |
| Autophagy | 3 | 16.016 |
| MOLECULAR PSYCHIATRY | 3 | 15.992 |
| ACS Nano | 1 | 15.881 |
| Journal of Thoracic Oncology | 1 | 15.609 |
| EUROPEAN JOURNAL OF HEART FAILURE | 1 | 15.534 |
(****)Publications in high influence journals are those published in journals with an impact factor equal or superior to 15 according to JCR 2020
Methodology and Definitions
Main indicators take into account articles, reviews, editorials and scientific letters published in journals indexed in Clarivate’s JCR 2020 (Journal Citation Reports), except CROWN and HCP10% which only take into account articles & reviews.
No ahead of print publications are taken into account.
